254 abstracts found.



Results filter

The impact of the COVID-19 pandemic on cancer diagnostic pathways in children, teenagers and young adults: a cohort study in England

Year:

Session type:

Defne Saatci1, Jason Oke1, Anthony Harnden1, Julia Hippisley-Cox1
1University of Oxford

Molecular screening of urine for Mismatch Repair deficient urothelial tumours; an under-appreciated cancer in Lynch syndrome

Year:

Session type:

Rachel Phelps1, John Burn1, Christine Hayes1, Richard Gallon1, Jo Pethick2, Fiona McRonald2, Steven Hardy2, Peter Gawthorpe1, Gillian Borthwick1, Mauro Santibanez-Koref1, Michael Jackson1
1Newcastle University, 2Public Health England

Circulating Tumour Cell Analysis to Evaluate Docetaxel Treatment Response and Resistance Markers in Prostate Cancer

Year:

Session type:

Caitlin Davies1
1Barts Cancer Institute

A global review of publicly available open-access skin cancer image datasets used in development of machine learning algorithms for skin cancer diagnosis

Year:

Session type:

David Wen1, Saad Khan2, Antonio Ji-Xu3, Hussein Ibrahim4, Luke Smith5, Jose Cabellero5, Luis Zepeda5, Les Mara5, Alastair Denniston1, Xiaoxuan Liu1, Rubeta Matin3
1University of Birmingham, 2Royal Berkshire NHS Foundation Trust, 3Oxford University Hospitals NHS Foundation Trust, 4University Hospitals Birmingham NHS Foundation Trust, 5Other

The influence of ethnicity on survival in malignant brain tumours in England: a population-based cohort study

Year:

Session type:

Hiba Wanis1, Elizabeth Davies1, Henrik Møller1, Keyoumars Ashkan1
1King’s College London (KCL)

Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1–4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements

Year:

Session type:

John Bridgewater1, Funda Meric-Bernstam2, Antoine Hollebecque3, Chigusa Morizane4, Juan W. Valle5, Thomas B. Karasic4, Thomas A. Abrams6, Robin Kate Kelley4, Philippe Cassier4, Junji Furuse4, Heinz-Josef Klümpen4, Heung-Moon Chang7, Li-Tzong Chen4, Yoshito Komatsu4, Kunihiro Masuda4, Daniel Ahn8, Yaohua He4, Nital Soni4, Karim A. Benhadji4, Lipika Goyal4
1UCL, 2MD Anderson Cancer Center, 3Institut Gustave Roussy, 4Other, 5University of Manchester, 6Dana-Farber Cancer Institute, 7Asan Medical Center, 8Mayo Clinic

Outcomes of patients with confirmed cancer of unknown primary: a 10-year analysis

Year:

Session type:

Aoife Gatenby1, Mark Stares1, Karin Purshouse2, Gillian Knowles1, Rachel Haigh1, Jenny Irvine1, Rebekah Patton1, Jo McGinty1, Alan Christie1, Marjory MacLennan1, Colin Barrie1, Sally Clive1
1Edinburgh Cancer Centre, 2University of Edinburgh

SELIMETRY: resensitising iodine refractory differentiated thyroid cancer to radioiodine

Year:

Session type:

Jon Wadsley1, Gemma Ainsworth2, Matthew Beasley3, Sarah Brown2, Amy Coulson2, Yong Du4, Kate Farnell5, Glenn Flux4, Kate Garcez6, Matthew Griffin7, Helen Howard2, Jennifer Marshall8, Laura Moss9, Kate Newbold4, Abigail Pascoe7, Jayne Swain2, Jan Taprogge4, Andrew Weaver10, Katie Wood11
1Sheffield Teaching Hospitals NHS Foundation Trust, 2University of Leeds, 3University Hospitals Bristol NHS Foundation Trust, 4Royal Marsden NHS Foundation Trust, 5Butterfly Thyroid Cancer Trust, 6The Christie NHS Foundation Trust, 7Nottingham University Hospitals NHS Trust, 8University Hospital Southampton NHS Foundation Trust, 9Velindre Cancer Centre, 10Oxford University Hospitals NHS Foundation Trust, 11Royal Surrey NHS Foundation Trust

Is A Body Shape Index (ABSI) associated with incident cancer? – Findings from the UK Biobank prospective cohort study

Year:

Session type:

Solange Parra Soto1, Fiona C Malcomson2, Jill P Pell1, Frederick K Ho1, Linda Sharp2, John C Mathers2, Carlos Celis-Morales1
1University of Glasgow, 2Newcastle University

Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis

Year:

Session type:

Emma Hazelwood1, Richard Martin1, James Yarmolinsky1
1University of Bristol

The IMPACT study Lynch Syndrome cohort – results after first round of screening.

Year:

Session type:

Elizabeth Page1, Ros Eeles2, Elizabeth Bancroft3
1The Institute of Cancer Research, 2Institute of Cancer Research (ICR), 3Royal Marsden NHS Foundation Trust

Fair treatment for all? Socioeconomic inequalities in HER2+ breast cancer treatment utilization

Year:

Session type:

Ruth Norris1, Rosie Dew2, Alastair Greystoke3, Nicola Cresti3, Adam Todd1, Linda Sharp1
1Newcastle University, 2University of Sunderland, 3Newcastle upon Tyne Hospitals NHS Foundation Trust

FOCUS4: lessons learnt from ten years of the first molecularly stratified adaptive trial platform in metastatic colorectal cancer

Year:

Session type:

Richard Adams1, Tim S Maughan2, Janet Graham3, Louise Brown4, David Fisher4, Jenny Seligmann5, Matthew Seymour5, Richard Kaplan4, Emma Yates4, Susan Richman5, Philip Quirke5, Rachel Butler6, Kai Keen Shiu4, Les Samuel7, Gary Middleton8, Harpreet Wasan9, Ewan Brown10, Fiona Collinson11, Robert Jones1, Michael Braun12, Richard Wilson13
1Cardiff University, 2University of Oxford, 3Beatson West of Scotland Cancer Centre, 4University College London (UCL), 5University of Leeds, 6North Bristol NHS Trust, 7NHS Grampian – Aberdeen Royal Infirmary, 8University of Birmingham, 9Imperial College London, 10Edinburgh Cancer Centre, 11Leeds Teaching Hospitals NHS Trust, 12Manchester University Hospitals NHS Foundation Trust, 13Beatson Institute for Cancer Research

FOCUS4-N: trial results and individual patient data meta-analysis of maintenance therapy versus active monitoring for patients with first line metastatic colorectal cancer

Year:

Session type:

Richard Adams1, David Fisher2, Janet Graham3, Jenny Seligmann4, Matt Seymour4, Richard Kaplan2, Emma Yates2, Susan Richman4, Philip Quirke4, Rachel Butler5, Ewan Brown6, Stephen Falk7, Fiona Collinson4, Richard Wilson8, Louise Brown2, Tim Maughan9
1Cardiff University, 2Medical Research Council (MRC) – Clinical Trials Unit, 3Beatson West of Scotland Cancer Centre, 4University of Leeds, 5North Bristol NHS Trust, 6NHS Lothian, 7University Hospitals Bristol NHS Foundation Trust, 8University of Glasgow, 9University of Oxford

FOCUS4-C: WEE1 inhibition in patients with TP53 and RAS dual mutant first line metastatic colorectal cancer: A randomized phase II trial comparing adavosertib (AZD1775) with active monitoring

Year:

Session type:

Jenny Seligmann1, David Fisher2, Louise Brown2, Janet Graham3, Richard Adams4, Richard Kaplan2, Emma Yates2, Susan Richman1, Philip Quirke1, Rachel Butler5, Michael Braun6, Robert Jones4, Ewan Brown7, Fiona Collinson1, Enric Domingo8, Andrew Blake8, Richard Wilson9, Matt Seymour1, Tim Maughan8
1University of Leeds, 2Medical Research Council (MRC) – Clinical Trials Unit, 3Beatson West of Scotland Cancer Centre, 4Cardiff University, 5North Bristol NHS Trust, 6Other, 7NHS Lothian, 8University of Oxford, 9University of Glasgow

Evaluation of a hypoxia-associated gene signature in the NIMRAD trial that randomised head and neck cancer patients to radiotherapy alone or with nimorazole 

Year:

Session type:

Joely Irlam1, Elisabet More1, Guy Betts2, Nick Slevin3, David Thomson3, Ananya Choudhury1, Catharine West1
1University of Manchester, 2Manchester University Hospitals NHS Foundation Trust, 3Other

The immune infiltrate, TGFb signalling and APC mutation determine complete response to radiation in rectal cancer

Year:

Session type:

Enric Domingo1, Sanjay Rathee2, Andrew Blake2, Leslie Samuel3, Graeme Murray4, David Sebag-Montefiore5, Simon Gollins6, Nicholas West5, Rubina Begum7, Marian Duggan7, Laura White7, Sylvana Hassanieh2, Susan Richman5, Phil Quirke5, James Robineau2, Keara Redmond8, Aikaterini Chatzipli9, Ultan McDermott9, Viktor Koelzer10, Simon Leedham2, Ian Tomlinson11, Philip Dunne8, Francesca Buffa2, Tim Maughan2
1University of Oxford, Oxford, UK, 2University of Oxford, 3NHS Grampian – Aberdeen Royal Infirmary, 4University of Aberdeen, 5University of Leeds, 6North Wales Cancer Treatment Centre, 7University College London (UCL), 8Queen’s University Belfast, 9Wellcome Sanger Institute, 10University of Zurich, 11University of Edinburgh

Endoscopically-delivered Purastat for the treatment of severe haemorrhagic radiation proctopathy: A case series

Year:

Session type:

Katherine White1, Caroline Henson1
1Manchester University Hospitals NHS Foundation Trust

Impact of Tucatinib on Progression Free Survival in Patients with HER2+ Metastatic Breast Cancer and Brain Metastases

Year:

Session type:

Thomas Bachelot1, Nancy Lin2, Rashmi Murthy3, Sara Hurvitz4, Virginia Borges4, Mafalda Oliveira4, Catherine Oakman4, Sarah Khan5, Cynthia Lynch4, Kelly Westbrook4, Catherine Doyle4, Matthea Reinish4, Marco Colleoni4, Dennis Slamon4, Gabriel Hortobagyi3, Eric Winer2, Jorge Ramos4, Wentao Feng4, Sibylle Loibl4
1Centre Léon Bérard, 2Dana-Farber Cancer Institute, 3MD Anderson Cancer Center, 4Other, 5Nottingham University Hospitals NHS Trust

Patient and treatment factors associated with adverse quality of life 2 years following radiotherapy – results from the REQUITE breast cancer patient cohort

Year:

Session type:

Tim Rattay1, Harkeran Jandu2, Colin Veal2, Petra Seibold3, David Azria4, Ananya Chaudhury5, Alison Dunning6, Dirk de Ruysscher4, Sara Gutierrez-Henriquez7, Philippe Lambin8, Tiziana Rancati4, Barry Rosenstein9, Elena Sperk4, R Paul Symonds2, Christopher Talbot2, Riccardo Valdagni4, Ana Vega4, Liv Veldeman4, Adam Webb2, Hilary Stobart4, Catharine West10
1University of Leicester, Leicester, UK, 2University of Leicester, 3German Cancer Research Center (DKFZ), 4Other, 5The Christie NHS Foundation Trust, 6University of Cambridge, 7Vall d’Hebron Institute of Oncology, 8Maastricht University, 9Icahn School of Medicine at Mount Sinai (ISMMS), 10University of Manchester

Physical activity interventions and health-related quality of life in women with breast cancer: A systematic literature review of the World Cancer Research Fund/American Institute of Cancer Research

Year:

Session type:

Dagfinn Aune1, Georgios Markozannes1, Leila Abar1, Katia Balducci1, Margarita Cariolou1, Neesha Nanu1, Ana Rita Vieira1, Steven Clinton2, Edward L Giovannucci2, Marc J Gunter3, Alan Jackson4, Ellen Kampman2, Viv Lund2, Anne McTiernan5, Kate Allen6, Nigel Brockton7, Helen Crocker6, Daphne Katsikioti6, Deirdre McGinley-Gieser7, Panagiota Mitrou6, Martin Wiseman6, Galina Velikova2, Wendy Demark-Wahnefried8, Teresa Norat1, Konstantinos K Tsilidis1, Doris S.M. Chan1
1Imperial College London, 2Other, 3International Agency for Research on Cancer (IARC), 4University of Southampton, 5Fred Hutchinson Cancer Research Center, 6World Cancer Research Fund International, 7American Institute for Cancer Research, 8University of Alabama at Birmingham

Patients’ experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC)

Year:

Session type:

Valerie Jenkins1, May Teoh2, Lucy Matthews2, Shirley May2, Manish Kothari2, David Bloomfield2, Fiona McKinna2, Charles Zammit2, Debbie Elwood-Sutton2, Stephanie Bell2, Heather Gage2, Regina Santos2, Elaine Stewart2, Dibendu Betal2, Kay Nicholson2, Judith Finlay2
1University of Sussex, 2Other

Associations between markers of social functioning and depression and quality-of-life among head and neck cancer survivors: findings from the HN5000 study

Year:

Session type:

Linda Sharp1, Liya Lu1, Laura-Jane Watson2, Sam Harding3, Joanne Patterson4
1Newcastle University, 2South Tyneside and Sunderland NHS Foundation Trust, 3North Bristol NHS Trust, 4University of Liverpool

Patients’ perspectives on a talking therapy for cancer aftercare

Year:

Session type:

Sheila Donovan1, Elisavet Moschopoulou1, Damien Ridge2, Trudie Chalder3, Imran Khan1, Stephanie Taylor1
1Queen Mary University of London, 2University of Westminster, 3King’s College London (KCL)

Cost-effectiveness of eRAPID eHealth intervention for online symptom management during chemotherapy

Year:

Session type:

Galina Velikova1, Bryony Dawkins1, Kate Absolom1, Lorraine Warrington1, Jenny Hewison1, Eleanor Hudson1, Andrea Gibson1, Marie Holmes1, Zoe Rogers1, Robert Carter1, Julia Brown1, Claire Hulme2
1University of Leeds, 2University of Exeter

Adiposity, exercise, diet, and outcomes after breast cancer diagnosis: World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) systematic literature review and meta-analysis.

Year:

Session type:

Margarita Cariolou1, Katia Balducci1, Nerea Becerra-Tomás1, Leila Abar1, Dagfinn Aune1, Georgios Markozannes1, Neesha Nanu1, Ana Rita Vieira1, Edward L Giovannucci2, Marc J Gunter3, Alan Jackson4, Ellen Kampman2, Viv Lund2, Kate Allen5, Nigel Brockton6, Helen Crocker5, Daphne Katsikioti5, Deirdre McGinley-Gieser6, Panagiota Mitrou5, Martin Wiseman5, Anne McTiernan7, Steven Clinton2, Teresa Norat1, Konstantinos K Tsilidis1, Doris S.M Chan1
1Imperial College London, 2Other, 3International Agency for Research on Cancer (IARC), 4University of Southampton, 5World Cancer Research Fund International, 6American Institute for Cancer Research, 7Fred Hutchinson Cancer Research Center

The International Cancer Benchmarking Partnership: The importance of international collaboration in addressing areas of cancer control to improve outcomes

Year:

Session type:

Harriet Hall1, Mathura Vithyananthan1, Charlotte Lynch1, Ellen Nolte2, Georgios Lyratzopoulos3, Sean McPhail4, Samantha Harrison1
1Cancer Research UK (CRUK), 2London School of Hygiene and Tropical Medicine, 3University College London (UCL), 4Public Health England

Clinical trials in screening, prevention and early diagnosis for cancer: A systematic mapping review

Year:

Session type:

Emma O’Dowd1, Samuel Merriel2, Vinton Cheng3, Sam Khan4, Lynne Howells4, Dipesh Gopal5, Elizabeth Roundhill3, David Baldwin1
1Nottingham University Hospitals NHS Trust, 2University of Exeter, 3University of Leeds, 4University of Leicester, 5Queen Mary University of London

A road map for the design of phase I clinical trials of radiotherapy-novel agent combinations

Year:

Session type:

Sarah Brown1, Samantha Hinsley2, Emma Hall3, Chris Hurt4, Richard Baird5, Martin Forster6, Andrew Scarsbrook1, Richard Adams4
1University of Leeds, 2University of Glasgow, 3Institute of Cancer Research (ICR), 4Cardiff University, 5Cancer Research UK (CRUK) Cambridge Centre, 6University College London Hospitals NHS Foundation Trust (UCLH)

Deficiencies in the reporting of early phase dose-finding oncology trials: findings from a rapid scoping review

Year:

Session type:

Christina Yap1, Olga Solovyeva1, Jonathan Martin2, Thubeena Manickavasagar2, Christopher Weir3, Shing Lee4, Munyaradzi Dimairo5, Rong Liu6, Andrew Kightley1, Johann de Bono2
1Institute of Cancer Research (ICR), 2Other, 3University of Edinburgh, 4Columbia University, 5University of Sheffield, 6Bristol-Myers Squibb Pharmaceuticals Ltd

Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension

Year:

Session type:

Ian Lewis1, Max Robinson2, Timothy J. Kendall3, Daniel J. Brierley4, Shujing Jane Lim2, Daniel O’Connor5, Abeer Shaaban6, An-Wen Chan7, David Harrison8
1National Cancer Research Institute (NCRI), 2Newcastle upon Tyne Hospitals NHS Foundation Trust, 3University of Edinburgh, 4University of Sheffield, 5Other, 6Queen Elizabeth Hospital Birmingham, 7University of Toronto, 8University of St Andrews

The spatial landscape of clonal expansion by confined somatic mutations in benign and malignant tissue

Year:

Session type:

Alastair Lamb1, Andrew Erickson2, Emelie Berglund3, Mengxiao He3, Joakim Lundberg3
1University of Oxford, 2Nuffied Department of Surgical Sciences, 3Other

A novel mechanism promotes actin patch formation to prevent chromatin bridge breakage in cytokinesis

Year:

Session type:

Sofia Balafouti1, George Zachos1, Eleni Petsalaki1
1Other

An ex vivo functional assay suite determines that ovarian tumour DNA damage response pathway signatures are heterogeneous and classify patient outcomes in ovarian cancer

Year:

Session type:

Thomas Walker1, Zahra Faraahi1, Marcus Price1, Amy Hawarden1, Dominique Jones1, Aiste McCormick2, Laura Woodhouse2, Connor Roberts1, Emma Crosbie1, Stephen Taylor1, Richard Edmondson1
1University of Manchester, 2Newcastle University

The role of genomic profiling by FoundationOne Liquid biopsy in matching patients to targeted early phase drug trials

Year:

Session type:

Laura Fitzgerald1, Lisa Brown-Schofield2, Alison Bridgewood2, Linda Hogarth2, Ruth Plummer2, Alastair Greystoke2, Yvette Drew2
1Newcastle University, 2Newcastle ECMC

Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101

Year:

Session type:

John Haanen1, James Larkin2, Toni Choueiri3, Laurence Albiges1, Brian Rini4, Michael Atkins1, Manuela Schmindinger1, Konstantin Penkov1, Despina Thomaidou1, Jing Wang5, Mariangela Mariani1, Alessandra di Pietro1, Robert Motzer6
1Other, 2Royal Marsden NHS Foundation Trust, 3Dana-Farber Cancer Institute, 4Vanderbilt-Ingram Cancer Center, 5Pfizer, 6Memorial Sloan-Kettering Cancer Center

Comprehensive evaluation of risk factors associated with immune checkpoint blockade-induced hepatitis

Year:

Session type:

Colin Lee1, Joanna Kucharczak1, Bruno De Paula1, George Mells1, Sarah Welsh1
1Cambridge University Hospitals NHS Foundation Trust

Harnessing liver-resident gamma delta T cells for immunotherapy of hepatocellular carcinoma

Year:

Session type:

Nekisa Zakeri1, Andrew Hall1, Leo Swadling1, Laura J Pallett1, Nathalie M Schmidt1, Mariana O Diniz1, Stephanie Kucykowicz1, Oliver E Amin1, Amir Gander1, Massimo Pinzani2, Brian R Davidson2, Alberto Quaglia2, Mala K Maini1
1University College London (UCL), 2Royal Free London NHS Foundation Trust

Trial recruitment challenges – lessons from the ROCS study of radiotherapy after stent insertion in incurable oesophageal cancer

Year:

Session type:

Anthony Byrne1, Douglas Adamson2, Noreen Hopewell-Kelly3, Lisette Nixon4, Debbie Forbes2, Mim Evans5, Catharine Porter4, Jane Blazeby6, Gareth Griffiths7, Annmarie Nelson1, Martina Svobodova4, Jim Fitzgibbon1, Stephen Thomas8, Anthony Millin9, Tom Crosby9, John Staffurth1, Christopher Hurt4
1Cardiff University, 2NHS Tayside, 3University of the West of England (UWE), 4Cardiff University – Centre for Trials Research, 5Cardiff and Vale University Health Board (CVUHB), 6University of Bristol, 7University of Southampton, 8Patient, 9Velindre Cancer Centre

Palliative radiotherapy after oesophageal cancer stent insertion: a multicentre, phase 3, randomised controlled trial (ROCS)

Year:

Session type:

Douglas Adamson1, Anthony Byrne1, Catharine Porter1, Jane Blazeby1, Gareth Griffiths1, Annmarie Nelson1, Bernadette Sewell1, Mari Jones1, Martina Svobodova1, Deborah Fitzsimmons1, Lisette Nixon1, Jim Fitzgibbon2, Stephen Thomas2, Anthony Millin3, Tom Crosby3, John Staffurth3, Christopher Hurt1
1Other, 2No affiliation, 3Velindre Cancer Centre

Urine metabolites predict the last weeks and days of life in lung cancer patients

Year:

Session type:

Seamus Coyle1, James Baker2, Hannah Coleman3, Elinor Chapman3, Brendan Norman3, Andrew Davison4, Stephen Mason3, David Hughes3, Mark Boyd3, John Ellershaw3, Chris Probert3
1Clatterbridge Cancer Centre NHS Foundation Trust, 2No affiliation, 3University of Liverpool, 4Liverpool University Hospitals NHS Foundation Trust

Resilience of elective cancer surgery systems during COVID-19 lockdowns: international, prospective cohort study of planned surgery for 15 tumour types in 61 countries

Year:

Session type:

James Glasbey1, . COVIDSurg Collaborative1
1University of Birmingham

Safety and feasibility of surgical salvage for local failures in non-operative management of rectal carcinoma. A preliminary data from phase 3 randomised OPERA trial.

Year:

Session type:

Arthur Sun Myint1, Brice Thamphya2, Jean Pierre Gerard2
1Clatterbridge Cancer Centre, 2Other

Minimally invasive or open oesophagectomy for localised oesophageal cancer: results of the ROMIO pragmatic randomised controlled trial

Year:

Session type:

Chris Metcalfe1, Jane Blazeby1, The ROMIO Study Group2
1University of Bristol, 2No affiliation

Identifying cancer patients’ journeys through health services prior and post COVID-19 pandemic using linked population-scale electronic health data.

Year:

Session type:

Rowena Griffiths1, Ashley Akbari2, Giles Greene3, Jun Han2, Dyfed Wyn Huws3, Monica Jones4, Mark Lawler5, Eva Morris6, Martin Rolles7, Janet Warlow3, Ronan Lyons2
1Swansea University Medical School, 2Swansea University, 3Other, 4University of Leeds, 5Queen’s University Belfast, 6University of Oxford, 7Swansea Bay University Health Board

Tumour reoxygenation by intratumoural injection of hydrogen peroxide (H₂O₂): a mechanism for enhanced radiosensitivity

Year:

Session type:

Samantha Nimalasena1, Selvakumar Anbalagan2, Carol Box2, Jessica K.R. Boult2, Nigel Bush2, Simon P. Robinson2, John Yarnold2, Navita Somaiah2
1Royal Marsden NHS Foundation Trust, 2Institute of Cancer Research (ICR)

Assessment of Y-H2AX and 53Bp1 Foci in peripheral Blood  Lymphocytes to predict subclinical Hematoxicity and Response in Somatostatin Receptor-Targetad Radionuclide Therapy for Advanced Gastroenter.

Year:

Session type:

Sarika Mehta1
1nil

Preventing weight gain to prevent breast cancer

Year:

Session type:

Mary Pegington1, Michelle Harvie2, Alan Davies1, David French1, Julia Mueller3, Anthony Howell1
1University of Manchester, 2Manchester University Hospitals NHS Foundation Trust, 3University of Cambridge

Evaluation of a faith-placed education intervention for bowel cancer screening in Muslim communities in the East of England

Year:

Session type:

Marimba Carr1, Daksha Trivedi2, Claire Thompson2, Nigel Smeeton2, Salman Waqar3, Tara Berger Gillam4, Iffat Tejani5
1NHS England, 2University of Hertfordshire, 3University of Oxford, 4Public Health England, 5No affiliation

Brain metastases in renal cell carcinoma. A 10-year retrospective study from a West Midlands tertiary centre

Year:

Session type:

Peijing Teo1, Iskandar Mohamed1, Simon Grumett1
1University Hospitals Birmingham NHS Foundation Trust